Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: Results of a multicenter prospective study

Urology

Volumn 82, Issue 6, 2013, Pages 1363-1369

  Gay, Hiram Alberto ^a   Michalski, Jeff M ^a   Hamstra, Daniel A ^b   Wei, John T ^b   Dunn, Rodney L ^b   Klein, Eric A ^c   Sandler, Howard M ^d   Saigal, Chris ^e   Litwin, Mark ^e   Kuban, Deborah ^f   Hembroff, Larry ^g   Chang, Peter ^h   Sanda, Martin G ⁱ  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g MICHIGAN STATE UNIVERSITY   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; HORMONE;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; ENDOCRINE DISEASE; EXPANDED PROSTATE CANCER INDEX COMPOSITE 26 QUESTIONNAIRE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; SEXUAL BEHAVIOR; URINE INCONTINENCE;

BIOPSY, NEEDLE; HUMANS; IMAGE-GUIDED BIOPSY; MALE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; QUALITY OF LIFE; UNNECESSARY PROCEDURES;

EID: 84888644807     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2013.06.062     Document Type: Article

References (27)

1. U.S. National Institutes of Health. Montgomery R. Abiraterone acetate, prednisone, and leuprolide acetate or goserelin before and during radiation therapy in treating patients with localized or locally advanced prostate cancer (NCT01023061). Available at: http://www.clinicaltrials.gov/ct2/show/NCT01023061? term=NCT01023061&26rank=1. Accessed: March 19, 2013.
2. Radiation Therapy Oncology Group. Michaelson MD. Phase III trial of dose escalated radiation therapy and standard androgen deprivation therapy (ADT) with a GnRH agonist vs. dose escalated radiation therapy and enhanced ADT with a GnRH agonist and TAK-700 for men with high risk prostate cancer. Available at: http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=1115. Accessed: March 19, 2013.
3. A.V. D'Amico, M.H. Chen, and A.A. Renshaw Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial JAMA 299 2008 289 295
4. C.U. Jones, D. Hunt, and D.G. McGowan Radiotherapy and short-term androgen deprivation for localized prostate cancer N Engl J Med 365 2011 107 118
5. J.W. Denham, A. Steigler, and D.S. Lamb Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial Lancet Oncol 12 2011 451 459
6. E.M. Horwitz, K. Bae, and G.E. Hanks Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 2008 2497 2504
7. M. Bolla, T.M. de Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
8. L. Souhami, K. Bae, M. Pilepich, and H. Sandler Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31 J Clin Oncol 27 2009 2137 2143
9. P. Warde, M. Mason, and K. Ding Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial Lancet 378 2011 2104 2111
10. A. Widmark, O. Klepp, and A. Solberg Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial Lancet 373 2009 301 308
11. M. Bolla, G. Van Tienhoven, and P. Warde External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study Lancet Oncol 11 2010 1066 1073
12. H.H. Pai, T. Pickles, and M. Keyes Randomized study evaluating testosterone recovery using short-versus long-acting luteinizing hormone releasing hormone agonists Can Urol Assoc J 5 2011 173 179
13. A.V. D'Amico, M.H. Chen, and A.A. Renshaw Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death Int J Radiat Oncol Biol Phys 75 2009 10 15
14. M.G. Sanda, R.L. Dunn, and J. Michalski Quality of life and satisfaction with outcome among prostate-cancer survivors N Engl J Med 358 2008 1250 1261
15. K.M. Szymanski, J.T. Wei, R.L. Dunn, and M.G. Sanda Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors Urology 76 2010 1245 1250
16. J.T. Wei, R.L. Dunn, and M.S. Litwin Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer Urology 56 2000 899 905
17. G.R. Norman, J.A. Sloan, and K.W. Wyrwich Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation Med Care 41 2003 582 592
18. M. Alemozaffar, M.M. Regan, and M.R. Cooperberg Prediction of erectile function following treatment for prostate cancer JAMA 306 2011 1205 1214
19. R.J. Stephens, D.P. Dearnaley, and R. Cowan The quality of life of men with locally advanced prostate cancer during neoadjuvant hormone therapy: data from the Medical Research Council RT01 trial (ISRCTN 47772397) BJU international 99 2007 301 310
20. NCCN. Prostate Cancer. Version 3.2012. Available at: https://www.nccn. org/professionals/physician-gls/pdf/prostate.pdf. Accessed May 13, 2012.
21. M. Janda, N. Gerstner, and A. Obermair Quality of life changes during conformal radiation therapy for prostate carcinoma Cancer 89 2000 1322 1328
22. B.K. Hollenbeck, J.T. Wei, and M.G. Sanda Neoadjuvant hormonal therapy impairs sexual outcome among younger men who undergo external beam radiotherapy for localized prostate cancer Urology 63 2004 946 950
23. B.K. Hollenbeck, R.L. Dunn, and J.T. Wei Neoadjuvant hormonal therapy and older age are associated with adverse sexual health-related quality-of-life outcome after prostate brachytherapy Urology 59 2002 480 484
24. L. Potters, T. Torre, R. Ashley, and S. Leibel Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy J Clin Oncol 18 2000 1187 1192
25. C.T. Chen, R.K. Valicenti, and J. Lu Does hormonal therapy influence sexual function in men receiving 3D conformal radiation therapy for prostate cancer? Int J Radiat Oncol Biol Phys 50 2001 591 595
26. H.W. Herr, and M. O'Sullivan Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy J Urol 163 2000 1743 1746
27. J. Evers, N. Kupper, and D. Kessing No long-term effects of hormonal therapy preceding brachytherapy on urinary function and health-related quality of life among prostate cancer patients Urology 76 2010 1150 1156